Hirotaka Shibata Selected Research

Body Weight (Weight, Body)

1/2023	Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
9/2022	The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.
2/2022	Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.
7/2019	Relationships between computed tomography-assessed density, abdominal fat volume, and glucose metabolism after sleeve gastrectomy in Japanese patients with obesity.
1/2018	Intestinal Mineralocorticoid Receptor Contributes to Epithelial Sodium Channel-Mediated Intestinal Sodium Absorption and Blood Pressure Regulation.
1/2014	Effects of a nonnutritive sweetener on body adiposity and energy metabolism in mice with diet-induced obesity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hirotaka Shibata Research Topics

Disease

26	Hyperaldosteronism (Conn Syndrome) 09/2023 - 10/2007
23	Hypertension (High Blood Pressure) 09/2023 - 03/2002
17	Adenoma (Adenomas) 10/2023 - 01/2003
16	Neoplasms (Cancer) 02/2023 - 02/2002
11	Hypokalemia 02/2023 - 02/2009
8	Obesity 05/2024 - 01/2014
6	Pheochromocytoma 02/2023 - 07/2006
6	Body Weight (Weight, Body) 01/2023 - 01/2014
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 11/2004
6	Cushing Syndrome 01/2019 - 04/2006
5	Diabetes Mellitus 03/2023 - 11/2016
5	Type 2 Diabetes Mellitus (MODY) 01/2023 - 01/2014
5	Proteinuria 03/2022 - 01/2012
4	Chronic Renal Insufficiency 03/2024 - 11/2021
3	Inflammation (Inflammations) 07/2022 - 10/2015
3	Rheumatoid Arthritis 10/2021 - 01/2016
3	Hyperplasia 01/2017 - 01/2011
3	Adrenocortical Adenoma (Disease, Conn's) 11/2004 - 02/2002
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2024 - 10/2023
2	AIDS-Related Complex (ARC) 11/2023 - 09/2023
2	Renal Insufficiency (Renal Failure) 09/2023 - 05/2022
2	Paraganglioma (Paragangliomas) 12/2021 - 01/2020
2	Non-alcoholic Fatty Liver Disease 02/2021 - 10/2020
2	Dyslipidemias (Dyslipidemia) 01/2020 - 12/2018
2	Heart Failure 09/2014 - 05/2012
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2010 - 02/2007
2	Adrenocortical Carcinoma 02/2009 - 04/2006
1	COVID-19 05/2024
1	Peripheral Nervous System Diseases (PNS Diseases) 04/2024
1	Chronic Kidney Failure (Chronic Renal Failure) 03/2024
1	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2023
1	Lupus Erythematosus Panniculitis (Panniculitis, Lupus) 10/2023
1	Albuminuria 09/2023
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2023
1	Hyperkalemia 01/2023
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2023
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 05/2022

Drug/Important Bio-Agent (IBA)

30	AldosteroneIBA 11/2023 - 10/2007
13	Hydrocortisone (Cortisol)FDA LinkGeneric 11/2023 - 02/2002
10	ReninIBA 11/2023 - 02/2009
10	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 09/2023 - 05/2012
8	Mineralocorticoid Receptor AntagonistsIBA 09/2023 - 01/2011
7	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 02/2007
7	EnzymesIBA 12/2021 - 01/2003
5	Adrenocorticotropic Hormone (ACTH)FDA Link 11/2023 - 01/2011
5	SaltsIBA 01/2023 - 01/2012
5	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 05/2012
4	CatecholaminesIBA 02/2023 - 07/2006
4	LipidsIBA 02/2023 - 07/2019
4	Hemoglobins (Hemoglobin)IBA 02/2022 - 10/2014
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 06/2003
4	SteroidsIBA 01/2014 - 01/2003
4	Estrogens (Estrogen)FDA Link 01/2011 - 11/2004
3	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2003
3	CreatinineIBA 09/2023 - 01/2020
3	esaxerenoneIBA 09/2023 - 01/2021
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2021
3	SodiumIBA 01/2023 - 01/2018
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/2022 - 05/2012
3	Messenger RNA (mRNA)IBA 01/2011 - 04/2006
3	Desoxycorticosterone (Deoxycorticosterone)IBA 05/2006 - 02/2002
3	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 11/2004 - 02/2002
3	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 06/2003 - 02/2002
2	Monoclonal AntibodiesIBA 01/2024 - 01/2020
2	AlbuminsIBA 09/2023 - 10/2020
2	Chromogranin AIBA 02/2023 - 07/2006
2	semaglutideIBA 09/2022 - 02/2022
2	PotassiumIBA 03/2022 - 01/2018
2	3-Iodobenzylguanidine (Iobenguane)IBA 12/2021 - 07/2006
2	CytokinesIBA 10/2021 - 04/2017
2	GlucocorticoidsIBA 01/2021 - 01/2016
2	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 01/2014
2	Triglycerides (Triacylglycerol)IBA 12/2018 - 02/2007
2	Eplerenone (Inspra)FDA LinkGeneric 01/2014 - 01/2012
2	Hormones (Hormone)IBA 01/2014 - 01/2003
2	Insulin-Like PeptidesIBA 01/2011 - 04/2006
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2011 - 04/2006
2	Estrogen Receptor alphaIBA 04/2009 - 11/2004
1	belimumabIBA 01/2024
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 11/2023
1	anifrolumabIBA 10/2023
1	18-hydroxycortisolIBA 10/2023
1	pro-brain natriuretic peptide (1-76)IBA 09/2023
1	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2023
1	AcetylglucosamineIBA 01/2023
1	Sodium-Glucose Transport ProteinsIBA 01/2023
1	finerenoneIBA 01/2023
1	Glucagon-Like Peptide-1 ReceptorIBA 09/2022
1	N-acylethanolaminesIBA 07/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2022
1	palmidrolIBA 07/2022

Therapy/Procedure

15	Adrenalectomy 09/2023 - 11/2010
12	Therapeutics 01/2024 - 05/2012
3	Renal Dialysis (Hemodialysis) 03/2024 - 05/2022
3	Operative Time 10/2014 - 12/2013
2	Aftercare (After-Treatment) 02/2022 - 04/2021
2	Gastrectomy 07/2019 - 01/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 03/2024
1	Radiofrequency Ablation 01/2023
1	Artificial Respiration (Mechanical Ventilation) 05/2022